ScripAscletis Pharma only joined the obesity field last September but has just presented early data for what could be a best-in-class oral GLP-1 agonist. Data from the Phase Ib MAD study show the Hong Kong
ScripViking Therapeutics, Inc. now looks poised to win the first round in a string of legal actions it has taken against Chinese firm Ascletis Pharma, Inc. , in which the US biotech alleged infringement
ScripBristol Myers Squibb Company and Sanofi recently joined the ranks of companies cutting costs and jobs in 2024, although not necessarily for the same reasons, as first quarter earnings season got un
ScripThe shift in terminology from NASH to MASH seems to be taking hold judging by public statements from companies working in the space, as well as some of the market analysts commenting on developments i